Another study confirmed these findings and found that TREM2 deficiency and anti-TREM2 mAb treatment delayed the growth of transplanted tumors and enhanced anti-PD-1 immunotherapy in mice by remodeling the tumor macrophage landscape (155). Here, TREM2 is linked to neoplasm.